Patents by Inventor Seiichi Tanida
Seiichi Tanida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080160553Abstract: The present invention relates to a method of preparing primary heart muscle cells, characterized by washing a fine fragmented heart tissue with a phosphate-buffered physiological saline to thereby eliminate non-heart muscle cells and then hemolyzing the heart tissue digested with a protease to thereby eliminate erythrocytes. According to this method, highly pure primary heart muscle cells can be conveniently obtained in a large amount from the heart of an animal embryo or newborn. By using the heart muscle thus prepared, apoptosis of heart muscle cells can be efficiently and highly sensitively detected. Thus, it is possible to efficiently screen candidate compounds for heart muscle cell apoptosis inhibitors, gp 130-mediated receptor agonists, heart muscle cell-protective signal enhancers, preventives and remedies for heart diseases.Type: ApplicationFiled: February 7, 2008Publication date: July 3, 2008Applicant: Takeda Pharmaceutical Company LimitedInventors: Haruhide Kimura, Nobuyuki Koyama, Seiichi Tanida, Tadamitsu Kishimoto, Keiko Takihara, Hisao Hirota
-
Patent number: 6794383Abstract: The present invention is intended to provide excellent preventives and/or remedies for heart diseases. Specifically, the present invention provides heart muscle cell apoptosis inhibitors, preventives and/or remedies for heart diseases, comprising a compound represented by the following formula: wherein R represents an optionally substituted hydrocarbon group, an optionally substituted aromatic heterocyclic group, or an optionally substituted amino group; or a salt thereof.Type: GrantFiled: February 27, 2003Date of Patent: September 21, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Haruhide Kimura, Seiichi Tanida, Tatsuhiko Kaneko
-
Publication number: 20040102613Abstract: The present invention provides a novel protein, a DNA thereof, a screening method with the use of the same, and so on. A compound or a salt thereof regulating the activity of the present protein is useful as a prophylactic and/or therapeutic agent for heart diseases and central nervous system diseases.Type: ApplicationFiled: September 17, 2003Publication date: May 27, 2004Inventors: Takashi Horiguchi, Seiichi Tanida
-
Publication number: 20030186304Abstract: It is an object of the present invention to provide a novel disease-associated gene and use of the protein thereof, etc. Specifically, the invention provides: (1) a screening method and a screening kit using the protein and a salt thereof; (2) a compound or a salt thereof controlling an activity of the protein, obtained by the screening method and the screening kit; (3) a neutralizing antibody regulating the activity of the protein; and (4) a medicine such as a preventive and a remedy for a heart disease.Type: ApplicationFiled: April 10, 2003Publication date: October 2, 2003Inventors: Nobuyuki Koyama, Seiichi Tanida, Toshifumi Watanabe
-
Publication number: 20030186971Abstract: The present invention is intended to provide excellent preventives and/or remedies for heart diseases.Type: ApplicationFiled: February 27, 2003Publication date: October 2, 2003Inventors: Harihide Kimura, Seiichi Tanida, Tatsuhiko Kaneko
-
Publication number: 20030175847Abstract: The present invention relates to a method of preparing primary heart muscle cells, characterized by washing a fine fragmented heart tissue with a phosphate-buffered physiological saline to thereby eliminate non-heart muscle cells and then hemolyzing the heart tissue digested with a protease to thereby eliminate erythrocytes. According to this method, highly pure primary heart muscle cells can be conveniently obtained in a large amount from the heart of an animal embryo or newborn. By using the heart muscle thus prepared, apoptosis of heart muscle cells can be efficiently and highly sensitively detected. Thus, it is possible to efficiently screen candidate compounds for heart muscle cell apoptosis inhibitors, gp 130-mediated receptor agonists, heart muscle cell-protective signal enhancers, preventives and remedies for heart diseases.Type: ApplicationFiled: December 16, 2002Publication date: September 18, 2003Inventors: Haruhide Kimura, Nobuyuki Koyama, Seiichi Tanida, Tadamitsu Kishimoto, Keiko Takihara, Hisao Hirota
-
Publication number: 20030108951Abstract: The present invention relates to a method of screening a drug by using a disease-associated gene product, an antibody to the disease-associated gene product, an antisense DNA that suppresses the expression of the disease-associated gene, etc.Type: ApplicationFiled: December 20, 2002Publication date: June 12, 2003Inventors: Nobuyuki Koyama, Seiichi Tanida, Toshifumi Watanabe
-
Patent number: 6004954Abstract: This invention relates to a compound of the following formula or a salt thereof, their production and use. ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen, a group bonding through a carbon atom, a group bonding through a nitrogen atom, a group bonding through an oxygen atom, or a group bonding through a sulfur atom; R.sup.3 represents hydrogen, halogen, a group bonding through a carbon atom, a group bonding through a nitrogen atom, a group bonding through an oxygen atom, or a group bonding through a sulfur atom; W represents an oxygen atom or sulfur atom; A represents a group forming a nitrogen-containing condensed ring at the 3,4- of a 1,4-thiazine ring; R.sup.1 and R.sup.2 may be combined to form a bivalent hydrocarbon group interrupted by one or more hetero atoms or an alkylene group.Type: GrantFiled: March 10, 1997Date of Patent: December 21, 1999Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuichi Furuya, Seiichi Tanida, Yoshikazu Ohta
-
Patent number: 5854407Abstract: Disclosed are (1) a structurally novel 6,9-hemiacetal- erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions br a salt thereof, which has an excellent gastrointestinal function promoting effect and is low in toxicity; (2) a process for preparing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which comprises reacting a 6,9-hemiacetal-erythromycin derivative or a salt thereof with an organism-derived oxidase; and (3) a gastrointestinal function promoting agent containing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof.Type: GrantFiled: June 7, 1995Date of Patent: December 29, 1998Assignee: Takeda Chemical CorporationInventors: Setsuo Harada, Yasunori Funabashi, Nobuhiro Inatomi, Shigeharu Tanayama, Seiichi Tanida
-
Patent number: 5506267Abstract: A compound of the invention is represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different, an acyl group; R.sup.3, R.sup.4, R.sup.6 and R.sup.7 are the same or different, hydrogen or an alkyl group; R.sup.5 is hydrogen, an alkyl group or a hydroxyl group which may optionally be protected, or R.sup.4 and R.sup.5 are combined to form a chemical bond; X is a carbonyl group or a sulfonyl group; Y is an amino acid sequence consisting of 1 to 7 amino acid residues which may optionally be protected and having optionally an intervening --SO.sub.2 NH--; n is an integer of 0 to 2, or a salt thereof.Type: GrantFiled: September 8, 1994Date of Patent: April 9, 1996Assignee: Takeda Chemical Industries, Ltd.Inventors: Tetsuya Aono, Koichi Yukishige, Seiichi Tanida
-
Patent number: 5478808Abstract: A compound of the formula: ##STR1## wherein each of R.sup.1 and R.sup.2 is hydrogen or aliphatic acyl, A is amino which may be protected, X is an amino acid sequence consisting of 1 to 10 amino acid residues which contain at least one amino acid residue having a water-solubility enhancing group, or a salt thereof has an activity of remarkably improving hematopoietic disorder and is useful as an immuno-stimulating agent or an agent for treating thrombocytopenia.Type: GrantFiled: December 28, 1993Date of Patent: December 26, 1995Assignee: Takeda Chemical Industries, Ltd.Inventors: Seiichi Tanida, Tsuneaki Hida, Mitsuhiro Wakimasu, Setsuo Harada, Koichi Yukishige
-
Patent number: 5478809Abstract: A compound of the formula: ##STR1## wherein each R.sup.1, R.sup.2 and R.sup.3 is an aliphatic acyl group, X is an amino acid sequence consisting of 1 to 5 amino acid residues which contain at least one acidic amino acid residue, n is an integer of 0 to 4, provided that when n is 0, X has glutamyl-glycyl at its N-terminal and when n is 1 or 2, the acidic amino acid residue is an acidic amino acid residue other than D-glutamyl, or a salt thereof has an activity of remarkably improving anhematopoiesis and is useful as an immuno-stimulating agent having a leukocyte-increasing activity.Type: GrantFiled: December 28, 1993Date of Patent: December 26, 1995Assignee: Takeda Chemical Industries, Ltd.Inventors: Seiichi Tanida, Tsuneaki Hida, Mitsuhiro Wakimasu
-
Patent number: 5470961Abstract: Disclosed are (1) a structurally novel 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which has an excellent gastrointestinal function promoting effect and is low in toxicity; (2) a process for preparing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which comprises reacting a 6,9-hemiacetal-erythromycin derivative or a salt thereof with an organism-derived oxidase; and (3) a gastrointestinal function promoting agent containing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof.Type: GrantFiled: March 19, 1993Date of Patent: November 28, 1995Assignees: Takeda Chemical Ind., Ltd., Kitasato KenkyushioInventors: Setsuo Harada, Yasunori Funabashi, Nobuhiro Inatomi, Shigeharu Tanayama, Seiichi Tanida
-
Patent number: 4540517Abstract: A compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represents hydrogen or methyl and X is ##STR2## provided that when R.sub.1 is hydrogen, R.sub.2 is hydrogen or methyl and X is ##STR3## and when R.sub.1 is methyl, R.sub.2 is methyl and X is ##STR4## is produced by cultivating a a microorganism belonging to the genus Streptomyces in a culture medium. Said compound is useful as an antimicrobial agent and so forth.Type: GrantFiled: December 2, 1983Date of Patent: September 10, 1985Assignee: Takeda Chemical Industries, Ltd.Inventors: Seiichi Tanida, Masayuki Muroi, Toru Hasegawa
-
Patent number: 4512975Abstract: Macbecin derivatives are produced by cultivating a microorganism of the genus Actinosynnema in a culture medium.The Macbecin derivatives are useful as antibacterial, antifungal or antiprotozoal agent.Type: GrantFiled: September 14, 1983Date of Patent: April 23, 1985Assignee: Takeda Chemical Industries, Ltd.Inventors: Toru Hasegawa, Masayuki Muroi, Seiichi Tanida
-
Patent number: 4450234Abstract: Novel antibiotic C-15003 PHM, which is produced by cultivating a microorganism belonging to the genus Nocardia and being capable of producing antibiotic C-15003 PHM, and novel C-15003 PHM acylate, which is produced by subjecting C-15003 PHM thus obtained to acylation reaction with an acylating agent, have antiprotozoan and antitumor activities.Type: GrantFiled: February 10, 1982Date of Patent: May 22, 1984Assignee: Takeda Chemical Industries, Ltd.Inventors: Toru Hasegawa, Motowo Izawa, Seiichi Tanida
-
Patent number: 4421687Abstract: Macbecin derivatives are produced by cultivating a microorganism of the genus Actinosynnema in a culture medium.The Macbecin derivatives are useful as antibacterial, antifungal or antiprotozoal agent.Type: GrantFiled: September 2, 1982Date of Patent: December 20, 1983Assignee: Takeda Chemical Industries, LimitedInventors: Toru Hasegawa, Masayuki Muroi, Seiichi Tanida
-
Patent number: 4373028Abstract: A novel antibiotic C-14482 A.sub.1 is produced by cultivating a microorganism belonging to the genus Nocardia and capable of producing Antibiotic C-14482 A.sub.1 is a culture medium, whereby Antibiotic C-14482 A.sub.1 is elaborated and accumulated in the culture medium and recovering the same antibiotic.Antibiotic C-14482 A.sub.1 is useful as a germicide or disinfectant.Type: GrantFiled: July 14, 1981Date of Patent: February 8, 1983Assignee: Takeda Chemical Industries, Ltd.Inventors: Eiji Higashide, Seiichi Tanida, Masayuki Muroi, Mitsuko Asai
-
Patent number: 4360462Abstract: A novel Antibiotic C-15003 is produced by cultivating a microorganism of the genus Nocardia.The Antibiotic C-15003 is useful as an antifungal agent or an antiprotozoan agent.Type: GrantFiled: October 22, 1981Date of Patent: November 23, 1982Assignee: Takeda Chemical Industries, Ltd.Inventors: Eiji Higashide, Mitsuko Asai, Seiichi Tanida
-
Patent number: 4331598Abstract: Novel antibiotic C-15003 PHM, which is produced by cultivating a microorganism belonging to the genus Nocardia and being capable of producing antibiotic C-15003 PHM, and novel C-15003 PHM acylate, which is produced by subjecting C-15003 PHM thus obtained to acylation reaction with an acylating agent, have antiprotozoan and antitumor activities.Type: GrantFiled: September 17, 1980Date of Patent: May 25, 1982Assignee: Takeda Chemical Industries, Ltd.Inventors: Toru Hasegawa, Motowo Izawa, Seiichi Tanida